Sunday, November 22, 2026

Novavax Stock Is 15% Down In The Last 5 Sessions

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Novavax Stock Is 15% Down In The Last 5 Sessions

(VIANEWS) - Shares of Novavax (NASDAQ: NVAX) slid by a staggering 15.14% in 5 sessions from $8.06 at -15.14, to $6.84 at 12:54 EST on Friday, after four successive sessions in a row of losses. NASDAQ is dropping 0.92% to $13,504.63, following the last session's upward trend.

Novavax's last close was $7.16, 90.67% below its 52-week high of $76.77.

About Novavax

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Earnings Per Share

As for profitability, Novavax has a trailing twelve months EPS of $-13.41.

Volume

Today's last reported volume for Novavax is 2702636 which is 55.62% below its average volume of 5737680.

Moving Average

Novavax's worth is way below its 50-day moving average of $7.93 and way under its 200-day moving average of $14.21.

More news about Novavax (NVAX).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 23 Jun 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.